Abstract
Overview
Introduction
More people than ever are living with HIV and AIDS in North America and
Western Europe. Over the next five years, a great variety of new HIV drugs are
expected to reach the market - early stage therapies will be simplified by new
products that will transform the market. For those with few treatment options
left, new pipeline products will redefine late stage therapy.
Scope
- Discussion of the epidemiology dynamics of HIV in the seven major markets,
as well as the changing unmet needs that result
- Assessment of late-phase clinical development compounds, competitors, and
opinion leader comments on trial design
- Forecasted sales of drugs in the antiretroviral market for the next 10
years
- Examination of the emerging drug classes including Entry Inhibitors and
Integrase Inhibitors
Report Highlights
The increased use of antiretroviral agents has been accompanied by a rise in
resistance to these drugs. Resistance generally falls into two categories:
natural and acquired. The factors surrounding the development of HIV
resistance are interrelated and include poor drug compliance, pharmacological
factors, and direct molecular drug resistance.
Atripla, approved in the US in July 2006, has been one of the greatest
developments in HIV therapy. A combination of two class leaders, Truvada and
Sustiva, the triple pill is the first to combine the components of HAART into
a single pill formulation taken once daily. Datamonitor forecasts it to reach
peak sales in excess of $2 billion.
Integrase inhibitors MK-0518 and GS-9137 look to be the most promising
candidates in the EI and others pipeline. Of the two, MK-0518 is the most
advanced and looks set to dominate the salvage market.
Reasons to Purchase
- Understand key drivers in the antiretroviral market and predict the future
performance of key compounds
- Explore the changing unmet needs of patients and clinical endpoints used
in current trial design
- Evaluate forecasts for the antiretroviral market to 2015, taking into
account key launch dates, patent expiries and generic incursion
| 
View Cart
